Fast Growing Mid-Tier Pharmaceutical Awards $2 Million Study to eResearchTechnology for Cardiac Safety Monitoring and Informatio
June 16 2004 - 9:02AM
PR Newswire (US)
Fast Growing Mid-Tier Pharmaceutical Awards $2 Million Study to
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Thorough Phase I ECG Study To Be Conducted
Over 90-Day Period eRT Leveraging Significant Experience with Later
Phase Development of Compound PHILADELPHIA, June 16
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has received an agreement for more than $2
million in cardiac safety monitoring and services from a fast
growing mid-tier pharmaceutical for one of its drug candidates in
clinical development. The agreement covers an extensive Phase I
study for which eRT is providing comprehensive support including
the provision, training and ongoing assistance required for
effective use of digital 12-lead Holter equipment designed to
facilitate 24-hour digital recording of cardiac safety data that is
subsequently provided to eRT for analysis. eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT(R) workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. The study is targeted for
completion over a 90-day period. "eRT is delighted to have been
selected for this demanding study, which provides an opportunity to
leverage our experience gained in providing cardiac safety services
for later phase, multi-center studies for this novel pain therapy,"
said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT. "This award illustrates the
trend toward drug developers working with a core laboratory, such
as eRT, across all phases of development to ensure consistency.
eRT's investments in scientific and operational resources,
technology, and partnerships combine to address the increasingly
sophisticated requirements of sponsors striving to achieve Best
Practices in cardiac safety for new drug development." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel this agreement at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affect the company's financial results can be found in the
company's Reports on Forms 10-K and 10-Q filed with the Securities
and Exchange Commission. DATASOURCE: eResearchTechnology, Inc.
CONTACT: Joan Sterlacci of eResearchTechnology, Inc.,
+1-908-203-6473, or Matt Hayden of Hayden Communications,
+1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles